What is Phyllanthus amarus used for in traditional medicine?

Phyllanthus amarus is primarily used in Southeast Asian, Indian Ayurvedic, and West African traditional medicine for liver disorders, jaundice, hepatitis, fevers, urinary tract complaints, and infections. In Malaysia it is known as 'dukung anak' and consumed as a water decoction for liver protection, while in Ayurveda it is called 'Bhumyamalaki' and prescribed as a hepatic tonic. These traditional indications align with preclinical findings of hepatoprotective and anti-inflammatory activity driven by its lignan and polyphenol content.

What are the key active compounds in Phyllanthus amarus?

The most pharmacologically significant compounds in Phyllanthus amarus are the lignans phyllanthin, hypophyllanthin, niranthin, nirtetralin, and phyltetralin, which are responsible for its hepatoprotective and antiviral properties. The plant also contains ellagitannins (geraniin, corilagin, amariin), flavonoids (quercetin, rutin), triterpenoids (lupeol, oleanolic acid), and phenolic acids. UPLC-ESI-MS analysis of ethanolic extracts has identified 51 distinct phytochemical compounds, with 23 partially quantified, though absolute concentrations vary with plant part and extraction method.

Is Phyllanthus amarus safe to take, and does it interact with medications?

Preclinical studies indicate low acute toxicity at tested doses, with no adverse effects on liver enzymes observed in animal models at 250–1000 mg/mL over 14 days. However, Phyllanthus amarus inhibits cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP2D6, meaning it can elevate blood levels of co-administered drugs such as warfarin, certain antidepressants, antipsychotics, and theophylline, potentially causing serious adverse effects. No human safety or tolerability trials have been completed, so individuals on prescription medications should consult a physician before use, and it should be avoided in pregnancy and lactation.

What does the research say about Phyllanthus amarus for liver disease?

Research on Phyllanthus amarus for liver disease is currently limited to preclinical (cell culture and animal) studies, with no published human randomized controlled trials identified. Animal models show that ethanolic extracts normalize elevated ALT and AST liver enzymes, reduce hepatic oxidative stress, and suppress NF-κB-mediated inflammatory signaling in liver tissue. While these findings are mechanistically promising and support traditional hepatoprotective use, clinical efficacy in humans with conditions such as hepatitis or non-alcoholic fatty liver disease has not been established.

What is the recommended dose of Phyllanthus amarus?

No standardized human dosage for Phyllanthus amarus has been established by any regulatory or clinical authority, as robust human pharmacokinetic and dose-finding trials have not been conducted. Preclinical animal studies have used doses of 250–500 mg/kg body weight, and in vitro models employed 250–1000 mg/mL extract concentrations, but these figures cannot be directly applied to human supplementation. Commercial preparations, where available, are sometimes standardized to phyllanthin content, but consumers should follow manufacturer guidance and ideally consult a healthcare provider, particularly given the herb's drug interaction potential via CYP450 inhibition.

How does Phyllanthus amarus compare to milk thistle for liver support?

While both are hepatoprotective herbs, Phyllanthus amarus works primarily through lignans (phyllanthin and hypophyllanthin) that suppress NF-κB inflammatory pathways and reduce CYP450-mediated oxidative stress, whereas milk thistle's silymarin acts mainly as a direct antioxidant and membrane stabilizer. Phyllanthus amarus shows additional anti-inflammatory benefits by inhibiting TNF-α, IL-1β, and PGE2, making it potentially more effective for inflammatory liver conditions. Research suggests they may be complementary rather than interchangeable, with choice depending on whether systemic inflammation or oxidative damage is the primary concern.

What is the most bioavailable form of Phyllanthus amarus supplement?

Ethanolic extracts (alcohol-based) demonstrate superior bioavailability and anti-inflammatory activity compared to aqueous or dried herb preparations, as the extraction process preserves and concentrates the key lignans phyllanthin and hypophyllanthin. Standardized extracts containing measured levels of these active compounds ensure consistent potency across batches. Liquid extracts or capsules of concentrated ethanolic extracts are generally preferred over whole plant powders for maximum hepatoprotective and anti-inflammatory effects.

Who should avoid Phyllanthus amarus, and are there specific populations at higher risk?

Individuals with active bleeding disorders or those taking anticoagulant medications should exercise caution due to potential platelet-modulating effects. Pregnant and nursing women should avoid supplementation without medical guidance, as safety data in these populations is limited. Additionally, people with severe kidney impairment or those scheduled for surgery should consult healthcare providers, as Phyllanthus amarus may affect drug metabolism through CYP450 enzyme modulation.

Phyllanthus amarus

Phyllanthus amarus contains hepatoprotective lignans—principally phyllanthin and hypophyllanthin—that suppress NF-κB, MAPK, and PI3K-Akt inflammatory signaling while inhibiting CYP450-mediated oxidative hepatotoxicity. Preclinical models demonstrate significant liver protection and anti-inflammatory activity, including dose-dependent DPPH radical inhibition up to 74.4% and normalization of elevated ALT/AST levels in treated animal groups, though robust human clinical trial data remain limited.

Category: Southeast Asian Evidence: 1/10 Tier: Preliminary

Phyllanthus amarus — Hermetica Encyclopedia

Origin & History

Phyllanthus amarus is native to tropical and subtropical regions of Asia, Africa, and the Americas, and is widely distributed across Southeast Asia including Malaysia, Vietnam, India, and the Philippines. It thrives in disturbed habitats, roadsides, and agricultural margins at low to mid-elevations, typically in humid, well-drained soils under full sun or partial shade. The plant has a long history of deliberate cultivation and wildcrafting in traditional medicine systems across its range, particularly in Ayurvedic, Jamu (Indonesian), and Vietnamese folk medicine traditions.

Historical & Cultural Context

Phyllanthus amarus has been integral to Ayurvedic medicine under the Sanskrit name 'Bhumyamalaki,' where it is classified as a bitter hepatic tonic and prescribed for jaundice, hepatitis, and urinary disorders for over two millennia. In Malaysian traditional medicine (Jamu/Malay ethnobotany) it is known as 'dukung anak' and consumed as a decoction for liver ailments, fevers, and sexually transmitted infections, while Vietnamese traditional practitioners employ it for liver disorders and as a cooling herb. Across West Africa, where it was later described by Schumacher and Thonning in the early 19th century, the plant is used for malaria, dysentery, and skin infections. Its global ethnobotanical footprint across at least three major traditional medicine systems—Ayurveda, Southeast Asian folk medicine, and African herbal practice—reflects convergent recognition of its hepatoprotective and anti-infective properties independent of cross-cultural exchange.

Health Benefits

- **Hepatoprotection**: Lignans phyllanthin and hypophyllanthin reduce hepatotoxic injury by downregulating CYP450-mediated oxidative stress and suppressing NF-κB-driven inflammatory cascades in liver tissue, with animal models demonstrating normalization of ALT and AST enzyme levels.
- **Anti-inflammatory Activity**: Ethanolic extracts inhibit pro-inflammatory mediators TNF-α, IL-1β, and PGE2 while downregulating COX-2 protein and mRNA expression in LPS-stimulated macrophages through blockade of TLR4/MyD88 upstream signaling.
- **Antioxidant Defense**: Polyphenols including geraniin, corilagin, and ellagitannins, alongside flavonoids quercetin and rutin, scavenge free radicals with DPPH inhibition reaching up to 74.4% at optimal extract concentrations.
- **Antiviral Support**: Niranthin, nirtetralin, and phyltetralin—minor lignans found in the whole plant—have demonstrated antiviral properties in preclinical settings, historically contextualizing traditional use for hepatitis B and jaundice management in Southeast Asian communities.
- **Anticancer Potential**: Ethanolic extracts induce G2/M cell cycle arrest in HepG2 hepatocellular carcinoma cells and modulate ribonucleotide/deoxyribonucleotide metabolism enzymes, with observed synergy at higher concentrations when combined with 5-fluorouracil.
- **Antihypertensive Effects**: Aqueous plant extracts have shown antihypertensive activity and improved cardiac function parameters in hypertensive animal models, suggesting cardiovascular benefits mediated partly through vasodilatory and antioxidant mechanisms.
- **Antimicrobial and Antiparasitic Activity**: Tannins including amariin and repansunic acid exhibit antibacterial properties, while ethanol extracts reduced parasitaemia and improved clinical parameters in rats infected with trypanosomiasis.

How It Works

The primary hepatoprotective and anti-inflammatory actions of Phyllanthus amarus are mediated by its lignan and polyphenol constituents, which suppress phosphorylation of NF-κB and its upstream regulators TLR4 and MyD88, thereby blocking transcription of pro-inflammatory cytokines TNF-α and IL-1β and inhibiting COX-2-dependent prostaglandin E2 synthesis. Concurrently, extracts attenuate phosphorylation of MAPK family members (JNK, ERK, p38) and PI3K-Akt pathway components in a dose-dependent manner, reducing cellular inflammatory amplification cascades. Antioxidant compounds—particularly ellagitannins geraniin and corilagin, and flavonoids quercetin and rutin—directly neutralize reactive oxygen species and modulate oxidative stress-sensitive gene expression in hepatocytes. Phyllanthin and hypophyllanthin additionally inhibit cytochrome P450 isoforms CYP1A2, CYP2C9, and CYP2D6, which can reduce phase I metabolic activation of hepatotoxic pro-drugs while simultaneously raising the risk of pharmacokinetic drug interactions.

Scientific Research

The body of evidence for Phyllanthus amarus is predominantly preclinical, comprising in vitro cell culture studies and animal model experiments, with no well-powered randomized controlled human clinical trials identified in the current literature. In vitro studies using HepG2 hepatocellular carcinoma cells demonstrated anti-tumor activity and G2/M cell cycle arrest, and UPLC-ESI-MS profiling identified and partially quantified 23 of 51 detected phytochemical constituents in ethanolic extracts. Animal studies include a chicken model evaluating n-hexane leaf extracts at 250–1000 mg/mL over 14 days, showing no adverse biochemical effects with normalization of elevated liver enzymes (AST reduced from 56.12±0.72 to near-control levels, P<0.05), and a rat trypanosomiasis model demonstrating reduced parasitaemia with ethanol extract administration. The overall evidence base is preliminary and insufficient to establish clinical efficacy or standardized dosing recommendations in humans without rigorous Phase II/III trial data.

Clinical Summary

No published human randomized controlled trials with defined sample sizes, effect sizes, or validated primary endpoints were identified for Phyllanthus amarus in the current evidence review. Preclinical efficacy has been examined in hepatotoxicity, hypertension, parasitic infection, and cancer cell models, with consistently positive directional findings but limited translational applicability due to species differences and lack of pharmacokinetic data in humans. The most quantitatively robust preclinical findings are enzyme normalization in hepatotoxicity models and up to 74.4% DPPH radical inhibition in antioxidant assays. Confidence in clinical recommendations remains low; the ingredient should be considered investigational for all therapeutic applications pending controlled human trials.

Nutritional Profile

Phyllanthus amarus is not a significant dietary macronutrient source but is phytochemically dense. Key lignan constituents include phyllanthin, hypophyllanthin, niranthin, nirtetralin, and phyltetralin, with concentrations varying substantially by plant part, growth stage, and extraction method. Ellagitannins (amariin, geraniin, corilagin, 1,6-digalloylglucopyranoside) and phenolic acids (phyllanthusiin D, repansunic acid) form the primary polyphenol fraction. Flavonoids quercetin and rutin contribute antioxidant capacity, while triterpenoids lupeol and oleanolic acid represent the terpene fraction. Minor constituents include phytol, β-tocopherol (vitamin E), saponins, and cardiac glycosides. UPLC-ESI-MS analysis of ethanolic extracts has identified 51 compounds with 23 quantified, though absolute concentrations in standardized units are not uniformly reported across studies. Bioavailability is enhanced by ethanolic versus aqueous extraction, but in vivo human absorption kinetics for individual compounds remain poorly characterized.

Preparation & Dosage

- **Traditional Whole-Plant Decoction**: The entire aerial part or whole plant is simmered in water (aqueous decoction) and consumed orally; this is the most historically common preparation in Malaysian, Vietnamese, and Indian folk medicine.
- **Ethanolic Extract (80% ethanol)**: Most studied research form for hepatoprotective and anti-inflammatory applications; 80% ethanol extraction has been noted to enhance polyphenol and lignan bioavailability compared to other solvents.
- **Aqueous Extract**: Used in preclinical antihypertensive and antiviral models; typically prepared as cold or hot infusions from dried aerial parts.
- **n-Hexane Leaf Extract**: Used in animal toxicity and antimicrobial studies at 250–1000 mg/mL; not recommended for general human supplementation due to solvent residue concerns and lack of human safety data.
- **Standardized Capsule/Tablet (commercial)**: Some commercial preparations are standardized to phyllanthin content; no universally accepted standardization percentage is established by regulatory bodies.
- **Preclinical Dose Reference**: Animal studies have employed 250–500 mg/kg body weight; direct human dose equivalents have not been validated through pharmacokinetic bridging studies.
- **Timing**: Traditional use typically involves twice-daily decoction consumption with meals; no clinical timing optimization data exist.

Synergy & Pairings

Phyllanthus amarus is traditionally combined with other hepatoprotective botanicals such as Silybum marianum (milk thistle) in integrative liver support formulations, where silymarin's flavonolignan-based mechanisms may complement phyllanthin's NF-κB suppression through additive antioxidant and anti-inflammatory effects on hepatocytes. In vitro data suggest synergistic anticancer activity when phyllanthin-rich extracts are combined with 5-fluorouracil in HepG2 cell models at higher concentrations, potentially through complementary cell cycle disruption and metabolic enzyme modulation. Curcumin from Curcuma longa is another proposed synergistic partner, as both compounds converge on NF-κB and MAPK pathway inhibition, though formal clinical combination studies have not yet been conducted.

Safety & Interactions

Preclinical evidence indicates a favorable short-term safety profile: n-hexane leaf extracts administered at 250–1000 mg/mL to chickens over 14 days produced no significant adverse effects on ALT, AST, ALP, or total protein levels, suggesting low acute hepatotoxicity at tested doses, though this cannot be directly extrapolated to humans. A clinically important pharmacokinetic concern is inhibition of CYP1A2, CYP2C9, and CYP2D6 isoenzymes, which could elevate plasma concentrations of co-administered drugs metabolized by these pathways—including warfarin (CYP2C9), certain antidepressants and antipsychotics (CYP2D6), and theophylline or clozapine (CYP1A2)—potentially causing adverse effects or toxicity. No human safety trials, maximum tolerated dose studies, or pharmacovigilance data are available, and use during pregnancy and lactation is not supported by any clinical evidence and should be avoided based on the precautionary principle. Individuals with pre-existing liver disease, those taking anticoagulants, narrow therapeutic index drugs, or antiretrovirals should consult a healthcare provider before use.